血速升颗粒治疗肿瘤相关性贫血的临床疗效观察
|
摘要
目的:观察血速升颗粒临床治疗肿瘤相关性贫血的有效性及安全性。方法:选取我院于2017年8月—2018年8月收治的54例肿瘤相关性贫血患者,随机分为对照组(27例)和治疗组(27例),对照组给予常规铁剂、叶酸及复合维生系B_(12)(VB_(12))等治疗,治疗组给予口服血速升颗粒,所有患者均连续治疗2周。观察两组患者治疗前后的相关血液指标、疲乏情况及KPS评分的改善。结果:治疗组的临床总有效率为85.19%,显著高于对照组74.07%。治疗后,两组患者的红细胞(RBC)及血红蛋白水平(Hb)均有显著性升高,且治疗组的变化更为显著(P<0.05);与治疗前相比,对照组患者治疗后WBC水平无显著性变化,而治疗组WBC水平显著性升高,同对照组相比差异有统计学意义(P<0.05);两组患者的KPS评分及神疲乏力改善情况均较治疗前有显著性提升,且治疗组的变化更为显著(P<0.05)。两组患者的不良反应发生率差异无统计学意义(P>0.05)。结论:血速升颗粒治疗肿瘤相关性贫血的临床疗效确切,能提高患者RBC、WBC及Hb水平,同时患者神疲乏力及生活质量得到明显提升,安全性较高,值得进行推广应用。
Objective:To observe the efficacy and safety of Xuesusheng Granule in the clinical treatment of tumor-associated anemia.Methods:A total of 54 patients with tumor-associated anemia admitted to our hospital from August 2017 to August 2018 were randomly divided into the control group(27 cases) and the treatment group(27 cases).The control group was given conventional iron, folic acid and VB_(12)treatment, the treatment group was given oral Xuesusheng Granules, and all patients were treated continuously for 2 weeks. The blood parameters, fatigue and card scores of the two groups were observed before and after treatment.Results:The total clinical effective rate of the treatment group was 85.19%, which was significantly higher than that of the control group(74.07%).After treatment, the red blood cells(RBC) and hemoglobin levels(Hb) of the two groups were significantly increased, and the changes in the treat ment group were more significant(P<0.05). Compared with before treatment, the WBC level of the control group had no significant change after treatment, while the WBC level of the treatment group was significantly increased, which was significantly different from the control group(P<0.05).Cardiac scores and improvement in fatigue in both groups were significantly higher than before treatment, and the changes in the treat ment group were more significant(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Xuesusheng Granule has a clinical curative effect on tumor-related anemia, which can improve the RBC, WBC and Hb levels. At the same time, the patient's fatigue and quality of life are significantly improved, and the safety is high.It is worthy of popularization and application.
Objective:To observe the efficacy and safety of Xuesusheng Granule in the clinical treatment of tumor-associated anemia.Methods:A total of 54 patients with tumor-associated anemia admitted to our hospital from August 2017 to August 2018 were randomly divided into the control group(27 cases) and the treatment group(27 cases).The control group was given conventional iron, folic acid and VB_(12)treatment, the treatment group was given oral Xuesusheng Granules, and all patients were treated continuously for 2 weeks. The blood parameters, fatigue and card scores of the two groups were observed before and after treatment.Results:The total clinical effective rate of the treatment group was 85.19%, which was significantly higher than that of the control group(74.07%).After treatment, the red blood cells(RBC) and hemoglobin levels(Hb) of the two groups were significantly increased, and the changes in the treat ment group were more significant(P<0.05). Compared with before treatment, the WBC level of the control group had no significant change after treatment, while the WBC level of the treatment group was significantly increased, which was significantly different from the control group(P<0.05).Cardiac scores and improvement in fatigue in both groups were significantly higher than before treatment, and the changes in the treat ment group were more significant(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Xuesusheng Granule has a clinical curative effect on tumor-related anemia, which can improve the RBC, WBC and Hb levels. At the same time, the patient's fatigue and quality of life are significantly improved, and the safety is high.It is worthy of popularization and application.
引文
[1] 赵伟汀, 张洁, 周晋华. 肿瘤相关性贫血中医药临床研究近况[J].中医药临床杂志, 2015, 27(11): 1636-1638.
[2] 黎壮伟. 补肾益髓法治疗肿瘤相关性贫血 40 例临床观察[J].湖南中医杂志, 2012, 28(3): 43-44.
[3] 杜林哲,朱余兵,刘赟心,等.重组人促红细胞生成素联合铁剂治疗围手术期贫血[J].药学与临床研究,2017,25(6):537-539.
[4] 王雪冰,李康.补肾健脾生血方治疗肿瘤相关性贫血临床疗效观察[J].辽宁中医药大学学报,2015,17(2):164-167.
[5] 中华人民共和国卫生部.中药新药临床研究指导原则[M].第2版.北京:人民卫生出版社,1995:137-140.
[6] Piper BF,Dibble SL,Dodd MJ,et al.The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer[J].Oncology Nursing Forum,1998,25(4):677-684.
[7] 张之南,沈悌.血液病诊断及疗效标准[M].北京:科学出版社,2007.
[8] 王莹,燕丽香,陈文彰.恶性肿瘤贫血相关因素分析[J].中国医药导刊,2013,15(7):1156-1157.
[9] 王希,夏冰,张翼鷟.肿瘤相关性贫血研究进展[J].中国肿瘤临床,2018,45(14):759-762.
[10] 刘彤华. 肿瘤相关性贫血相关因素分析[J].中国实验诊断学, 2013, 17(9): 1688-1691.
[11] 黄志惠, 吴玉霞, 费飞. 加味当归补血汤与常规西药治疗肿瘤相关性贫血的临床对比研究[J].临床和实验医学杂志, 2017, 16(8): 787-790.
[12] 崔利格, 魏素菊. 细胞因子在肿瘤相关性贫血中的作用机制研究进展[J].肿瘤防治研究,2014,41(9):1049-1053.
[13] 刘现军.温肾健脾补血法治疗肿瘤相关性贫血的临床疗效观察[J].中国处方药, 2015,13(11):95-96.
[14] 黄金菊,周跃华,殷东风.阿胶治疗癌症患者肿瘤相关性贫血临床研究[J].亚太传统医药,2018,14(7):167-169.
[15] 宋春燕,王翠英,沈凤梅.归脾汤治疗肿瘤相关性贫血临床研究[J].中医学报,2013, 28(3):320-321.
[16] 付烊,运强,朱学明.中西医治疗肿瘤相关性贫血进展[J].中医学报,2016,31(9):1270-1273.
[17] 侯丽,倪磊,马薇,等.益中生血胶囊治疗肿瘤相关性贫血的临床观察[J].北京中医药大学学报:中医临床版,2012,(2):27-30.
[18] 刘明峰,杨金霞,刘笑,等.血速升颗粒治疗贫血模型鼠的实验研究[J].河北医科大学学报, 2018, 39(7):822-827.
[2] 黎壮伟. 补肾益髓法治疗肿瘤相关性贫血 40 例临床观察[J].湖南中医杂志, 2012, 28(3): 43-44.
[3] 杜林哲,朱余兵,刘赟心,等.重组人促红细胞生成素联合铁剂治疗围手术期贫血[J].药学与临床研究,2017,25(6):537-539.
[4] 王雪冰,李康.补肾健脾生血方治疗肿瘤相关性贫血临床疗效观察[J].辽宁中医药大学学报,2015,17(2):164-167.
[5] 中华人民共和国卫生部.中药新药临床研究指导原则[M].第2版.北京:人民卫生出版社,1995:137-140.
[6] Piper BF,Dibble SL,Dodd MJ,et al.The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer[J].Oncology Nursing Forum,1998,25(4):677-684.
[7] 张之南,沈悌.血液病诊断及疗效标准[M].北京:科学出版社,2007.
[8] 王莹,燕丽香,陈文彰.恶性肿瘤贫血相关因素分析[J].中国医药导刊,2013,15(7):1156-1157.
[9] 王希,夏冰,张翼鷟.肿瘤相关性贫血研究进展[J].中国肿瘤临床,2018,45(14):759-762.
[10] 刘彤华. 肿瘤相关性贫血相关因素分析[J].中国实验诊断学, 2013, 17(9): 1688-1691.
[11] 黄志惠, 吴玉霞, 费飞. 加味当归补血汤与常规西药治疗肿瘤相关性贫血的临床对比研究[J].临床和实验医学杂志, 2017, 16(8): 787-790.
[12] 崔利格, 魏素菊. 细胞因子在肿瘤相关性贫血中的作用机制研究进展[J].肿瘤防治研究,2014,41(9):1049-1053.
[13] 刘现军.温肾健脾补血法治疗肿瘤相关性贫血的临床疗效观察[J].中国处方药, 2015,13(11):95-96.
[14] 黄金菊,周跃华,殷东风.阿胶治疗癌症患者肿瘤相关性贫血临床研究[J].亚太传统医药,2018,14(7):167-169.
[15] 宋春燕,王翠英,沈凤梅.归脾汤治疗肿瘤相关性贫血临床研究[J].中医学报,2013, 28(3):320-321.
[16] 付烊,运强,朱学明.中西医治疗肿瘤相关性贫血进展[J].中医学报,2016,31(9):1270-1273.
[17] 侯丽,倪磊,马薇,等.益中生血胶囊治疗肿瘤相关性贫血的临床观察[J].北京中医药大学学报:中医临床版,2012,(2):27-30.
[18] 刘明峰,杨金霞,刘笑,等.血速升颗粒治疗贫血模型鼠的实验研究[J].河北医科大学学报, 2018, 39(7):822-827.